Bayer Reports Encouraging Findings in Asundexian Stroke Treatment Study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 24 2025
0mins
Source: WSJ
Positive Clinical Trial Results: Bayer announced successful late-stage clinical trial results for asundexian, a drug aimed at preventing strokes.
Combination Therapy Efficacy: The 50mg once-daily medication, when used with antiplatelet therapy, effectively reduced stroke risk without causing major bleeding, a common issue with other blood thinners.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
